The Complex Interaction Between Polycystic Ovary Syndrome and Hereditary Angioedema: Case Reports and Review of the Literature

Imagem de Miniatura
Arquivos
art_IAHN-AUN_The_Complex_Interaction_Between_Polycystic_Ovary_Syndrome_and_2017.PDF (204.78 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2017
Editora
LIPPINCOTT WILLIAMS & WILKINS
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
OBSTETRICAL & GYNECOLOGICAL SURVEY, v.72, n.7, p.417-424, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Importance Hereditary angioedema (HAE) is a rare but severe disease, with high risk of death, and attacks have been associated to high estrogen levels. Polycystic ovary syndrome (PCOS) is a common hyperandrogenic condition, which is frequently treated with combined oral contraceptives. Objective The aim of this study was to describe 2 clinical cases of young women diagnosed as having PCOS who developed HAE attacks after the introduction of combined estrogen-progestin pills to treat PCOS symptoms. Evidence Acquisition Literature review of sex hormones' role in genesis of HAE attacks and possible mechanisms involved. Results In the cases reported, after initiation of combined contraceptives, patients presented with facial swelling with airway involvement (laryngeal edema) and abdominal pain. They had a familial history of angioedema and normal C1 inhibitor (C1-INH) levels, leading to the diagnosis of HAE with normal C1-INH (HAEnC1-INH) or HAE type III. After suspension of exogenous estrogen, patients remained asymptomatic from HAE. Conclusions and Relevance HAEnC1-INH is an estrogen-dependent form of HAE. It is well established that exogenous estrogen triggers attacks of all types of HAE. However, this is the first description of the association between PCOS and HAE, in which PCOS could be masking HAE symptoms. We propose that PCOS might have a protective role regarding HAE attacks, because of its particular hormonal features, that is, hyperandrogenism and relative stable levels of estradiol. The use of combined estrogen-progestin compounds in women with PCOS and HAE must be avoided, and treatment must be individualized. Target Audience Obstetricians and gynecologists, family physicians. Learning Objectives After completing this activity, the learner should be better able to evaluate for hereditary angioedema (HAE) in patients with recurrent angioedema attacks and abdominal pain, particularly when they are under exogenous estrogen treatment; ask patients about personal or familial history of angioedema attacks before prescribing exogenous estrogen; recall that isolated progestins can be used as long-term prophylaxis to HAE patients; and explain that hyperandrogenism of polycystic ovary syndrome could mask HAE symptoms.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21258
Referências
  1. Azziz R, 2004, J CLIN ENDOCR METAB, V89, P2745, DOI 10.1210/jc.2003-032046
  2. Azziz R, 2003, OBSTET GYNECOL, V101, P995, DOI 10.1016/S0029-7844(02)02725-4
  3. Azziz R, 2009, FERTIL STERIL, V91, P456, DOI 10.1016/j.fertnstert.2008.06.035
  4. Betschel S, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-50
  5. Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546
  6. Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7
  7. Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064
  8. Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1
  9. Bork K, 2015, ALLERGY, V70, P1004, DOI 10.1111/all.12648
  10. Bouillet Laurence, 2010, Allergy Asthma Clin Immunol, V6, P17, DOI 10.1186/1710-1492-6-17
  11. Broekmans FJ, 2006, BJOG-INT J OBSTET GY, V113, P1210, DOI 10.1111/j.1471-0528.2006.01008.x
  12. Caballero T, 2011, J INVEST ALLERG CLIN, V21, P333
  13. Caccia S, 2014, PEDIAT ALLER IMM PUL, V27, P159, DOI 10.1089/ped.2014.0425
  14. Christiansen SC, 2015, ALLERGY ASTHMA PROC, V36, P145, DOI 10.2500/aap.2015.36.3831
  15. Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380
  16. Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510
  17. Craig Timothy, 2012, World Allergy Organ J, V5, P182, DOI 10.1097/WOX.0b013e318279affa
  18. DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595
  19. Davis AE, 2008, MOL IMMUNOL, V45, P4057, DOI 10.1016/j.molimm.2008.06.028
  20. de Maat S, 2014, INT J LAB HEMATOL, V36, P374, DOI 10.1111/ijlh.12222
  21. Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092
  22. DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1
  23. DONALDSON VH, 1966, PEDIATRICS, V37, P1017
  24. Eckes B, 1999, EUR J INTERN MED S1, V10, P187
  25. FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076
  26. Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098
  27. FRANK MM, 1976, ANN INTERN MED, V84, P580
  28. GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602
  29. Giavina-Bianchi P, 2015, CLIN EXP ALLERGY, V45, P1142, DOI 10.1111/cea.12551
  30. Giavina-Bianchi P, 2011, CLINICS, V66, P1627, DOI 10.1590/S1807-59322011000900021
  31. Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
  32. Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211
  33. Huang A, 2010, FERTIL STERIL, V93, P1938, DOI 10.1016/j.fertnstert.2008.12.138
  34. Jayasena CN, 2014, NAT REV ENDOCRINOL, V10, P624, DOI 10.1038/nrendo.2014.102
  35. Joseph K, 2013, J ALLERGY CLIN IMMUN, V132, P470, DOI 10.1016/j.jaci.2013.03.026
  36. Joseph K, 2009, J ALLERGY CLIN IMMUN, V124, P143, DOI 10.1016/j.jaci.2009.02.006
  37. LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1
  38. LEVI M, 1991, J CLIN INVEST, V88, P1155, DOI 10.1172/JCI115416
  39. Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X
  40. Osler W, 1888, AM J MED SCI, V95, P362, DOI 10.1097/00000441-188804000-00004
  41. PERRICONE R, 1992, CLIN EXP IMMUNOL, V90, P401
  42. PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1
  43. Renne T, 2005, J IMMUNOL, V175, P3377
  44. Riedl MA, 2013, J ALLER CL IMM-PRACT, V1, P427, DOI 10.1016/j.jaip.2013.06.004
  45. ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708
  46. SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802
  47. Schunkert H, 1997, CIRCULATION, V95, P39
  48. Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181
  49. Yip J, 1992, Australas J Dermatol, V33, P35, DOI 10.1111/j.1440-0960.1992.tb00050.x
  50. Zawadski JK, 1992, POLYCYSTIC OVARY SYN, P377
  51. Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313
  52. Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - LIM/58
Artigos e Materiais de Revistas Científicas - LIM/60
Carregar mais